Clinical trials: Abnormal Uterine Bleeding
- Condition Abnormal Uterine Bleeding
- Funder type Industry (pharma, biotech, devices)
- Age group Children (under 18)
Dysfunctional Uterine Bleeding
COMPARISON OF A NEW FORMULATION OF GOSERELIN (Pepti 3.6 mg) to Zoladex® 3.6 mg
The comparator drug (Zoladex 3.6 mg) is approved for use as a thinning agent for the endometrium prior to endometrial ablation. The dosing recommendation is one or two depots with each depot given four weeks apart.
- Trial name
- NCT04428684
- Testing
- Pepti 3.6 mg
- Where
- 5 sites in Ukraine
- Volunteers
- 80 people
- Sponsor
- Peptigroupe Inc.
Postpartum Hemorrhage
RUBY Post-Market Registry on the Jada® System
The RUBY Study is a multicenter, observational, post-market registry designed to collect observational data on patients treated with the Jada System in the post-market setting.
- Trial name
- RUBY (NCT04995887)
- Testing
- Jada® System
- Where
- 16 sites in United States
- Volunteers
- 809 people
- Sponsor
- Alydia Health
Abnormal Uterine Bleeding
Management of Abnormal Uterine Bleeding
Abnormal uterine bleeding "AUB" describes all abnormal forms of menstrual bleeding which may result from several causes including anovulation, problems related to pregnancy, infections, vaginal and cervical abnormalities, uterine…
- Trial name
- NCT06369012
- Testing
- Mefenamic acid 500 mg
- Where
- Egypt
- Volunteers
- 130 people
- Sponsor
- Egymedicalpedia